SMS Pharmaceuticals Ltd Q2 FY27 Revenue Rises 30% to ₹316 Crore

SMS Pharmaceuticals Ltd reported Q2 FY27 revenue from operations of ₹316.08 crore, up 30% year on year from ₹242.43 crore, while PAT increased 57% to about ₹40 crore and EBITDA margin reached 21%. The September-quarter performance was disclosed in its investor presentation published on November 4, 2026.

What did SMS Pharmaceuticals report for Q2 FY27?

SMS Pharmaceuticals reported revenue from operations of ₹316.08 crore in Q2 FY27, compared with ₹242.43 crore in Q2 FY26. This represents 30% year-on-year growth for the quarter ended September 30, 2026. The company’s investor presentation also cited consolidated revenue of ₹316.09 crore, a difference of ₹0.01 crore due to rounding.

Operating performance improved faster than revenue. EBITDA was reported at ₹68 crore, against ₹48 crore a year earlier, reflecting 40% year-on-year growth. The company reported PAT of ₹40 crore, compared with ₹25 crore in Q2 FY26, representing 57% growth. The detailed consolidated comparison reported operating profit of ₹67.66 crore and net profit of ₹39.85 crore, which are consistent with the rounded figures in the presentation.

The board approved unaudited standalone and consolidated results for the second quarter of FY27 on November 4. The company also said it had not published an earnings-call transcript for the quarter at the time of the presentation, meaning the reported information is based on disclosed financial results and presentation material rather than management commentary from a transcript.

How did SMS Pharmaceuticals' margins change in Q2 FY27?

SMS Pharmaceuticals expanded both operating and net profit margins during Q2 FY27. EBITDA margin was 21%, up 145 basis points from 20% in Q2 FY26. PAT margin improved to 13% from 10%, an expansion of 217 basis points from the prior-year quarter.

The increase in EBITDA of 40% exceeded the 30% rise in revenue, while PAT growth of 57% was higher still. These reported relationships explain the margin improvement visible in the quarterly figures. The presentation stated that FY27 EBITDA margins are expected to exceed the company’s earlier guidance, indicating the company’s disclosed outlook for operating profitability.

Margins are an important measure for pharmaceutical manufacturers because revenue growth alone does not show how much of additional sales is retained as operating or net profit. For investors, the Q2 figures show that SMS Pharmaceuticals reported higher profitability ratios alongside its revenue growth, although the available material does not provide a detailed quarter-specific breakdown of the drivers behind the improvement.

What was disclosed in the approved financial results?

SMS Pharmaceuticals disclosed separate standalone and consolidated figures in the board-approved financial results, which should be distinguished from the presentation’s revenue-from-operations metrics. The standalone results showed total income of ₹526.12 crore and net profit of ₹60.27 crore for the quarter ended September 30, 2026.

On a consolidated basis, the approved results showed total income of ₹895.22 crore and net profit of ₹87.61 crore. These total-income and net-profit figures are separately reported in the filing and are not directly described in the supplied material as the same presentation metrics used for the ₹316.08 crore revenue from operations and approximately ₹40 crore PAT comparison.

The board also accepted the resignation of Company Secretary Thirumalesh Tumma, effective at the close of business on November 4, 2026. Manohar Mollama was appointed Company Secretary and Compliance Officer effective November 5, 2026. This was a governance and compliance update announced alongside the financial results.

What capex has SMS Pharmaceuticals planned through FY27?

SMS Pharmaceuticals has planned total capital expenditure of ₹280 crore to be completed by FY27. The capex plan was disclosed in the company’s Q2 FY27 investor presentation and is one of the stated operational commitments accompanying the quarterly performance update.

Capital expenditure is relevant because it can shape manufacturing capacity, product development infrastructure, and future operational requirements. However, the supplied presentation extract does not provide a project-wise allocation, spending completed to date, financing details, or expected financial contribution from this ₹280 crore programme.

For shareholders, the capex target must be assessed alongside the company’s profitability and cash-flow position. The source material notes concerns around cash from operations relative to debt-servicing expenses, but it does not provide a quantified operating cash-flow figure, debt amount, or a revised funding plan for the planned capex. Those details therefore cannot be inferred from the disclosed information.

How does the Q2 update matter for investors and the pharmaceutical sector?

SMS Pharmaceuticals' Q2 update matters because it reported growth across revenue, EBITDA and PAT, with improved operating and net margins. Revenue rose by ₹73.65 crore year on year, EBITDA increased by ₹20 crore, and PAT increased by ₹15 crore based on the rounded presentation figures.

The information provided does not include a share-price movement, valuation metric, analyst estimate, or peer comparison. Therefore, no direct conclusion can be drawn about the market’s reaction to the results. The disclosed results instead provide a financial snapshot of the company’s quarterly operations and a stated margin outlook for FY27.

The company scheduled an investor conference call for November 5, 2026, at 12 noon IST to discuss Q2 and H1 FY27 performance and outlook. That call was announced through filings with BSE and NSE under Regulation 30. Management commentary from that event could provide further context on margins, the capex schedule, demand conditions, and funding priorities.

Conclusion

SMS Pharmaceuticals reported a stronger Q2 FY27 on the operating measures highlighted in its investor presentation. Revenue from operations increased 30% to ₹316.08 crore, EBITDA rose 40% to ₹68 crore, and PAT grew 57% to approximately ₹40 crore. EBITDA margin of 21% and PAT margin of 13% were both higher than in Q2 FY26.

The next disclosed event to watch is the November 5, 2026 investor conference call, where management was scheduled to discuss Q2 and H1 FY27 results. Investors may look for more detail on the company’s expectation that FY27 EBITDA margins will exceed earlier guidance, the execution timeline for ₹280 crore of planned capex, and cash-flow considerations linked to the investment programme.